5) CHM have been able to achieve successful manufacturing in very large quantities- giving CHM ~1000 doses per expansion, once again another big tick.
6) CHM Have been able to demonstrate evidence of 28 day persistence of the NK cells. Excellent.
7) CHM Have been able to demonstrate enhanced cytotoxic activity in both preclinical models and now also in the phase 1 clinical trial, just another plus that the market has missed.
8) CHM have been able to demonstrate that the NK cells expanded through this platform have enhanced metabolic activation and expression of activating NK receptors, proving that the NK platform works.
These points are just some of the pluses for CHM NK platform that the market just does not get, but I believe that when it eventually does and with the continued good results in the trails we will have a massive rerate. Extremely under valued IMHO. I think if CHM was listed in the USA the market cap would probably many bags higher as they understand BIO-TECH stocks a lot better.
5) CHM have been able to achieve successful manufacturing in...
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
